A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.

Slides:



Advertisements
Similar presentations
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
Advertisements

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved DOC_1A.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
EnligHTN™ I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou,
National Institute for Health and Clinical Excellence.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Steffen Desch Thomas Okon, Diana Heinemann, Konrad Kulle, Karoline Röhnert, Melanie Sonnabend, Martin Petzold, Ulrike Müller, Gerhard Schuler, Ingo Eitel,
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
A Controlled Trial of Renal Denervation for Resistant Hypertension
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Relationship between coronary and renal artery disease and associated risk factors in hypertensive and diabetic patients undergoing coronary angiography.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Journal Club February 7, 2014 Sadie T. Velásquez, MD.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Prairie Cardiovascular, Springfield, IL US
Total Occlusion Study of Canada (TOSCA-2) Trial
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
The Vessix Global Clinical Program REDUCE-HTN: REINFORCE
Critical Appraisal of Devices for the Management of Hypertension
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Thomas F. Lüscher, FESC, FAHA, FRCP
Potential conflicts of interest
OneShot™ Renal Denervation System
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Critical Appraisal of the Current Ongoing Study Designs
From ESH 2016 | POS 7D: Jan Rosa, MD
Renal Denervation Next Steps
Renal Denervation: the St. Jude experience
Jan B. Pietzsch1, Benjamin P. Geisler1, Murray D. Esler 2
Renal Unit-Careggi University Hospital-Florence-Italy
Accelerating a Revolution in the Treatment of Hypertension
Medtronic Cardiovascular,
Mapping Sympathetic Nerve Distribution for
Chemical Renal Denervation Update and Future Directions
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc.
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
The Anglo Scandinavian Cardiac Outcomes Trial
Renal Sympathetic Denervation: The Academic View
CVRx Baroreflex Activation Therapy:
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
Renal Denervation Two Late-Breaking Clinical Trials.
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Systolic Blood Pressure Intervention Trial (SPRINT)
Section VIII. Ambulatory BP Measurement
Renal Denervation Rises From the Ashes
Resistant Hypertension: Initial Combinations of Medications
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN) Philipp Lurz,
Controlling High Blood Pressure
MK-0954 PN948 NOT APPROVED FOR USE (date)
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Controlling Elevated Blood Pressure
pulmonary embolism protocol -- EMB review
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Volume 377, Issue 9771, Pages (March 2011)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Clinician Referral Training
The following slides highlight a report by Dr
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Presentation transcript:

A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy Cardiology Research Institute, Tomsk NRMC, Russian Academy Of Sciences

INTRODUCTION Hypertension remains a main health problem in the world despite a highly developed drug treatment. Antihypertensive pharmacotherapy is ineffective in patients with resistant hypertension (~10%) and in patients with persisting non- compliance (~ 30%). A conceptually new treatment of hypertension - endovascular renal denervation (RDN) – potentially may help to improve blood pressure control in both above areas of ineffective drug treatment. Regrettably, RDN failed in large Symplicity HTN-3 trial

WRONG ANATOMICAL MODE OF CONVENTIONAL RDN In our opinion, RDN failed because it was done in anatomically wrong way Specifically, 4-6 point ablations were done equally distributed within main trunk of renal artery This mode may only be effective if all renal nerves closely follow the course of renal artery from aorta to the kidney with equal circumferential density and within 2 mm from its lumen (depth of the RF treatment)  

REAL ANATOMY OF RENAL PLEXUS In contrast, the surgical studies show that renal plexus has a triangular form with wide base directed toward aorta and apex converging to the kidney   i.e. proximally, the majority of the nerves proceed obliquely at a distance from renal artery and join mainly its distal part [Page, 1935. Oldham, 1950].

DISTAL MODE OF RDN We developed a distal mode of RDN in segmental branches of renal artery:   Ablation catheter is advanced sequentially into segmental branches, and 2 or 4 separate point treatments are performed in each branch depending on its diameter: 4 - if the diameter is 4 mm or greater 2 - if the diameter is less than 4 mm   Plus 2 additional treatments in the distal trunk to guarantee sufficient completeness of neural damage when at least one branch was treated with 2 ablations

Our trial of distal RDN vs conventional mode for treatment of resistant hypertension (NCT02667912) A Double Blind Randomized Controlled Study With 2 Parallel Groups Inclusion Criteria: 1. Men and women 18-80 years 2. BP >= 160/100 mmHg despite at least 3 drugs including a diuretic 3. Given written informed consent Exclusion Criteria: 1. Secondary hypertension 2. 24 h mean systolic BP <135 mmHg (ABPM) 3. eGFR < 30 mL/min/1.73 m2 4. Severe renal artery stenosis 5. Any other clinically important disorders preventing study participation (investigator's assessment) The primary study outcome: The between-group difference in the changes of 24h mean systolic BP (ABPM) from baseline to 6 m Secondary outcomes: The changes of office BP, daytime, and nighttime BPs, serum creatinine, eGFR and resistant index (RI) of renal blood flow assessed by Doppler flowmetry 6 months FU AE, office BP, ABPM, DFM, serum creatinine, eGFR randomization 1:1 Intervention Baseline evaluation office BP, ABPM, DFM, serum creatinine, eGFR Patients with resistant hypertension Conventional RDN Distal RDN Then we compare our distal mode of renal denervation with conventional form of the intervention in double blind randomized controlled study. We used the same eligibility criteria as in the Symplicity trial.

Assessed for eligibility (n=65) THE STUDY PROFILE Enrollment Assessed for eligibility (n=65) Excluded (n=10) ¨  Not meeting inclusion criteria (n=4) ¨  Declined to participate (n=6) Randomized (n=55) Allocation Allocated to distal RDN(n=28) ¨ Received allocated intervention (n=28) Allocated to conventional RDN(n=27) ¨ Received allocated intervention (n=27) Follow-Up Fifty five patients were randomized. Twenty eight – in the group of distal therapy, twenty seven – in the group of conventional denervation. Fifty one patient completed 6 months follow up. Twenty seven patients after distal treatment and twenty four – after conventional intervention. Lost to follow-up (n=1) ¨ Inability to get to the study site (n=1) Lost to follow-up (n=3) ¨ Inability to get to the study site (n=1) ¨ Consent withdrawal (n=2) Analysis Analysed (n=27) Analysed (n=24)

Treatment of segmental branches SAFETY OF DISTAL RDN Treatment of segmental branches Control angiography Technical success was 100% in both groups Intraoperational angiography did not show any significant damage of segmental branches of renal artery after distal treatment There was only one complication - a post-punctional pseudoaneurysm in patient treated by distal technique.

PRIMARY STUDY OUTCOME (final results) Technical success was 100% in both groups A magnitude of the decrease in 24h mean BP was significantly (2 times) greater after distal therapy then after conventional RDN No major safety issue was observed P<0,05

SECONDARY OUTCOMES P<0,05 Daytime, nighttime, and office BPs also decreased more in the group of distal therapy. then in the group of conventional renal denervation. The difference reached statistical significance for daytime systolic BP

CONCLUSIONS Renal denervation treatment is significantly less effective in the trunk of renal artery than in segmental branches The failure of Symplicity HTN-3 trial may be fully explained by anatomically wrong mode of the intervention in the trunk of renal artery Future development of RDN needs to be re-directed to producing devices for use in segmental branches of renal artery